Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study
Open Access
- 15 July 2025
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115603
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma US Inc
- Astellas Pharma
- Pfizer
- Pfizer Inc
This publication has 18 references indexed in Scilit:
- Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid TumorsClinical Pharmacokinetics, 2024
- SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerAnnals of Oncology, 2023
- Squamous cell lung cancer: Current landscape and future therapeutic optionsCancer Cell, 2022
- Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaNew England Journal of Medicine, 2021
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and TreatmentMayo Clinic Proceedings, 2019
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerJournal of Thoracic Oncology, 2018
- Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancerLung Cancer, 2017
- BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpointsStatistics in Medicine, 2017
- Clinicopathologic Features of Advanced Squamous NSCLCJournal of Thoracic Oncology, 2016